Market Closed -
Borsa Istanbul
16:09:53 14/05/2024 BST
|
5-day change
|
1st Jan Change
|
55.9
TRY
|
-0.71%
|
|
-6.68%
|
+19.24%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Capitalization
1 |
4,605
|
15,514
|
14,064
|
Enterprise Value (EV)
1 |
4,237
|
15,020
|
14,658
|
P/E ratio
|
11.4
x
|
14.4
x
|
30.9
x
|
Yield
|
2.39%
|
2.15%
|
-
|
Capitalization / Revenue
|
1.84
x
|
2.85
x
|
1.73
x
|
EV / Revenue
|
1.69
x
|
2.76
x
|
1.8
x
|
EV / EBITDA
|
13.4
x
|
19.5
x
|
17.5
x
|
EV / FCF
|
135,345,055
x
|
-55,964,319
x
|
-16,658,566
x
|
FCF Yield
|
0%
|
-0%
|
-0%
|
Price to Book
|
3.59
x
|
5.56
x
|
2.91
x
|
Nbr of stocks (in thousands)
|
300,000
|
299,496
|
300,000
|
Reference price
2 |
15.35
|
51.80
|
46.88
|
Announcement Date
|
04/03/22
|
03/03/23
|
05/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,180
|
1,795
|
2,150
|
2,501
|
5,445
|
8,152
|
EBITDA
1 |
91.45
|
210.6
|
245.7
|
316.9
|
768.8
|
836.3
|
EBIT
1 |
79.32
|
194.9
|
226.2
|
273.4
|
712
|
575.5
|
Operating Margin
|
6.72%
|
10.86%
|
10.52%
|
10.93%
|
13.07%
|
7.06%
|
Earnings before Tax (EBT)
1 |
7.038
|
159.1
|
216.8
|
301.4
|
1,073
|
262.4
|
Net income
1 |
6.524
|
143.1
|
207
|
310.8
|
1,080
|
454.6
|
Net margin
|
0.55%
|
7.97%
|
9.63%
|
12.43%
|
19.84%
|
5.58%
|
EPS
|
-
|
-
|
4.141
|
1.343
|
3.601
|
1.515
|
Free Cash Flow
|
-
|
77.69
|
-84.68
|
31.3
|
-268.4
|
-879.9
|
FCF margin
|
-
|
4.33%
|
-3.94%
|
1.25%
|
-4.93%
|
-10.79%
|
FCF Conversion (EBITDA)
|
-
|
36.89%
|
-
|
9.88%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
54.28%
|
-
|
10.07%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
0.3667
|
1.111
|
-
|
Announcement Date
|
12/07/21
|
12/07/21
|
12/07/21
|
04/03/22
|
03/03/23
|
05/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
161
|
78.6
|
109
|
-
|
-
|
594
|
Net Cash position
1 |
-
|
-
|
-
|
368
|
494
|
-
|
Leverage (Debt/EBITDA)
|
1.759
x
|
0.3731
x
|
0.4426
x
|
-
|
-
|
0.7102
x
|
Free Cash Flow
|
-
|
77.7
|
-84.7
|
31.3
|
-268
|
-880
|
ROE (net income / shareholders' equity)
|
-
|
79.6%
|
51.6%
|
33.7%
|
53.2%
|
9.23%
|
ROA (Net income/ Total Assets)
|
-
|
25%
|
17.3%
|
10.7%
|
15.3%
|
5.13%
|
Assets
1 |
-
|
571.4
|
1,200
|
2,908
|
7,044
|
8,868
|
Book Value Per Share
|
-
|
-
|
11.10
|
4.280
|
9.310
|
16.10
|
Cash Flow per Share
|
-
|
-
|
1.170
|
1.730
|
1.300
|
0.2200
|
Capex
1 |
7.22
|
38.2
|
84.1
|
125
|
312
|
528
|
Capex / Sales
|
0.61%
|
2.13%
|
3.91%
|
4.98%
|
5.74%
|
6.47%
|
Announcement Date
|
12/07/21
|
12/07/21
|
12/07/21
|
04/03/22
|
03/03/23
|
05/04/24
|
|
1st Jan change
|
Capi.
|
---|
| +19.24% | 524M | | +31.06% | 682B | | +30.35% | 586B | | -3.42% | 364B | | +18.02% | 327B | | +4.27% | 285B | | +15.53% | 240B | | +10.16% | 209B | | -8.14% | 203B | | +8.12% | 165B |
Other Pharmaceuticals
|